| 1.22 Data as of Jun 19 | -0.09 / -6.87%Today’s Change | 0.75 Today|||52-Week Range 9.44 | -85.10% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Medical Specialties | MARKET CAP $74.8M |
Company Description
Celsion Corp. provides oncology drug development services. It is an oncology drug development company dedicated to the development and commercialization of cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. The company's lead product, ThermoDox, is a liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers. Celsion was founded by Augustine Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Employees

Shareholders
| Mutual fund holders | 4.36% |
| Other institutional | 24.32% |
| Individual stakeholders | 2.40% |
Top Executives
| Michael H. Tardugno | President, Chief Executive Officer & Director |
| Gregory L. Weaver, MBA, CPA | Chief Financial Officer & Senior Vice President |
| Nicholas Borys, MD | Chief Medical Officer & Vice President |
| Frank Gary Renshaw, MD | Executive Medical Director |
| Raj Prabhakar, MBA | Executive Director-Strategic Planning |